DHPC | LPI
Oncology
Local Prescribing Information (Oncology):
Pertuzumab Trastuzumab Injection [Phesgo®]
Atezolizumab Injection [Tecentriq®]
Bevacizumab Injection [Avastin® and Syndyma®]
Obinutuzumab Injection [Gazyva®]
Trastuzumab for Injection [Herclon™ and Biceltis®]
Trastuzumab emtansine for Injection [Kadcyla®]
Pertuzumab Injection [Perjeta®]
Rituximab Injection [Ristova® and Ikgdar®]
Alectinib Capsules [Alecensa®]
Erlotinib Tablets I.P. [Tarceva®]
Capecitabine Tablets I.P. [Xeloda®]
Safety Update Information for Healthcare Professionals (Oncology):
DHPC Xeloda Important Safety update of PI for Xeloda_DPD deficiency dated 3rd October 2018
DHPC Tecentriq Atezolizumab Injection 1200MG/20ML restriction to Tecentriq 1L Cisplatin-Ineligible mUC Indication dated July 23, 2018
Disclaimer - Kindly note that it takes approximately up to 6 months to implement the revised PI in commercial stocks imported into India after submission to the health authorities. All PIs notified to or approved by the CDSCO are published on this website for all the HCPs prescribing Roche drugs within 10 calendar days.